Bone and soft tissue sarcomas, tumors of the skinBone and soft tissue sarcomas, tumors of the skinСаркомы костей, мягких тканей и опухоли кожи2219-46142782-3687Publishing House ABV Press56610.17650/2782-3687-2022-14-2-28-35SOFT TISSUE SARCOMASСАРКОМЫ МЯГКИХ ТКАНЕЙRole of vascular endothelial growth factors in pathogenesis of soft tissue sarcomas: literature reviewРоль факторов роста эндотелия сосудов в патогенезе сарком мягких тканей: обзор литературыhttps://orcid.org/0000-0002-9616-8996SheikoE. A.ШейкоЕ. А.
Russian Federation

Elena Aleksandrovna Sheiko

63 14th liniya, Rostov-on-Don 344037

Елена Александровна Шейко

344037 Ростов-на-Дону, ул. 14-я линия, 63

esheiko@inbox.ruhttps://orcid.org/0000-0002-3711-8155KaplievaI. V.КаплиеваИ. В.
Russian Federation

63 14th liniya, Rostov-on-Don 344037

44037 Ростов-на-Дону, ул. 14-я линия, 63

https://orcid.org/0000-0003-3618-6890FrantsiyantsE. M.ФранциянцЕ. М.
Russian Federation

63 14th liniya, Rostov-on-Don 344037

44037 Ростов-на-Дону, ул. 14-я линия, 63

https://orcid.org/0000-0002-7302-7031VashchenkoL. N.ВащенкоЛ. Н.
Russian Federation

63 14th liniya, Rostov-on-Don 344037

44037 Ростов-на-Дону, ул. 14-я линия, 63

https://orcid.org/0000-0003-0252-4708SurikovaE. I.СуриковаЕ. И.
Russian Federation

63 14th liniya, Rostov-on-Don 344037

44037 Ростов-на-Дону, ул. 14-я линия, 63

https://orcid.org/0000-0001-9557-3685SagatelyanS. A.СагателянС. А.
Russian Federation

63 14th liniya, Rostov-on-Don 344037

44037 Ростов-на-Дону, ул. 14-я линия, 63

National Medical Research Centre of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России070720221420707202207072022Copyright ©; 2022, Sheiko E.A., Kaplieva I.V., Frantsiyants E.M., Vashchenko L.N., Surikova E.I., Sagatelyan S.A.Copyright ©; 2022, Шейко Е.А., Каплиева И.В., Франциянц Е.М., Ващенко Л.Н., Сурикова Е.И., Сагателян С.А.2022Sheiko E.A., Kaplieva I.V., Frantsiyants E.M., Vashchenko L.N., Surikova E.I., Sagatelyan S.A.Шейко Е.А., Каплиева И.В., Франциянц Е.М., Ващенко Л.Н., Сурикова Е.И., Сагателян С.А.https://creativecommons.org/licenses/by/4.0https://sarbon.abvpress.ru/jour/article/view/566

During tumor growth, one of the leading functions in providing oxygen and nutrients to the neoplasm belongs to the system of its angiogenesis. Vascular endothelial growth factor (VEGF) is a major inducer of angiogenesis and appears to be a key modulator of the antitumor response. Indeed, VEGF modulates the innate and adaptive immune response through direct interaction with the tumor and indirectly through modulation of protein expression on endothelial cells or vascular permeability. This review provides the main characteristics of the VEGF family, ligands and their receptors. The role of VEGF in the pathogenesis of soft tissue sarcomas and their relapses is discussed, and possible therapeutic approaches in the treatment of these tumors, directed at the VEGF system, are considered.

Во время роста опухоли одна из ведущих функций в обеспечении кислородом и питательными веществами новообразования принадлежит системе ее ангиогенеза. Фактор роста эндотелия сосудов (vascular endothelial growth factor, VEGF) является основным индуктором ангиогенеза и, по-видимому, ключевым модулятором противоопухолевого ответа. Действительно, VEGF модулирует врожденный и адаптивный иммунный ответ посредством прямого взаимодействия с опухолью и косвенно, путем модуляции экспрессии белка на эндотелиальных клетках или проницаемости сосудов. В этом обзоре приводятся основные характеристики семейства VEGF, лигандов и их рецепторов. Обсуждается роль VEGF в патогенезе сарком мягких тканей и их рецидивов, рассматриваются возможные терапевтические подходы в лечении этих опухолей, направленные на систему VEGF.

sarcomasrelapsesvascular endothelial growth factorvascular endothelial growth factor receptorantiangiogenic therapyсаркомырецидивыфактор роста эндотелия сосудоврецептор фактора роста эндотелия сосудовантиангиогенная терапияFerlay J., Colombet M., Soerjomataram I. et al. Cancer statistics for the year 2020: An overview. Int J Cancer 2021 Apr 5. DOI: 10.1002/ijc.33588.Jo V.Y., Doyle L.A. Refinements in sarcoma classification in the current 2013 World Health Organization Classification of tumours of soft tissue and bone. Surg Oncol Clin N Am 2016;25(4):621–43. DOI: 10.1016/j.soc.2016.05.001.Eastley N., Green P.N., Ashford R.U. Soft tissue sarcoma. BMJ 2016;352:i436. DOI: 10.1136/bmj.i436.Malignant neoplasms in Russia in 2020 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, 2021. 252 p. (In Russ.).Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021. 252 с.Du X.H., Wei H., Zhang P. et al. Heterogeneity of soft tissue sarcomas and its implications in targeted therapy. Front Oncol 2020;10:564852. DOI: 10.3389/fonc.2020.564852.Roland C.L. Soft tissue tumors of extremity. Surg Clin North Am 2020;100(3):669–80. DOI: 10.1016/j.suc.2020.02.015.Spolverato G., Callegaro D., Gronchi A. Defining which patients are at high risk for recurrence of soft tissue sarcoma. Curr Treat Options Oncol 2020;21(7):56. DOI: 10.1007/s11864-020-00753-9.Benberin V.V., Baizakov B.T., Shanazarov N.A., Zinchenko S.V. Soft tissue sarcomas – a modern view of the problem. Vestnik Avicenny = Avicenna Bulletin 2019;21(2): 291–7. (In Russ.). DOI: 10.25005/2074-0581-2019-21-2-291-297.Бенберин В.В., Байзаков Б.Т., Шаназаров Н.А, Зинченко С.В. Саркомы мягких тканей – современный взгляд на проблему. Вестник Авиценны 2019;21(2):291–7.Soomers V., Husson O., Young R. et al. The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes. ESMO Open 2020;5(1):e000592. DOI: 10.1136/esmoopen-2019-000592.Lugano R., Ramachandran M., Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77(9):1745–70. DOI: 10.1007/s00018-019-03351-7.Brownstein J.M., DeLaney T.F. Malignant soft-tissue sarcomas. Hematol Oncol Clin North Am 2020;34(1):161–75. DOI: 10.1016/j.hoc.2019.08.022.Hoang N.T., Acevedo L.A., Mann M.J., Tolani B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res 2018;10:1089–114. DOI: 10.2147/CMAR.S159641.Bourcier K., Le Cesne A., Tselikas L. et al. Basic knowledge in soft tissue sarcoma. Cardiovasc Intervent Radiol 2019;42(9):1255–61. DOI: 10.1007/s00270-019-02259-w.Damerell V., Pepper M.S., Prince S. Molecular mechanisms underpinning sarcomas and implications for current and future therapy. Signal Transduct Target Ther2021;6(1):246. DOI: 10.1038/s41392-021-00647-8.Geindreau M., Ghiringhelli F., Bruchard M. Vascular endothelial growth factor, a key modulator of the anti-tumor immune response. Int J Mol Sci 2021;22(9):4871. DOI: 10.3390/ijms22094871.Franzyants E.M., Rastorguev E.E., Sheiko E.A. Some aspects of angiogenesis of brain tumors. Annaly klinicheskoj i eksperimental’noj nevrologii = Annals of Clinical and Experimental Neurology 2021;15(2):50–8. (In Russ.). DOI: 10.25692/ACEN.2021.2.7.Франциянц Е.М., Рoсторгуев Э.Е., Шейко Е.А. Некоторые аспекты ангиогенеза опухолей головного мозга. Анналы клинической и экспериментальной неврологии 2021;15(2):50–8.Melincovici C.S., Boşca A.B., Şuşman S. et al. Vascular endothelial growth factor (VEGF) – key factor in normal and pathological angiogenesis. Rom J Morphol Embryol 2018;59(2):455–67.Korablev R.V., Vasiliev A.G. Neoangiogenesis and tumor growth. Rossijskie biomedicinskie issledovaniya = Russian Biomedical Research 2017;2(4):3–10. (In Russ.).Кораблев Р.В., Васильев А.Г. Неоангиогенез и опухолевый рост. Российские биомедицинские исследования 2017;2(4):3–10.Karampinis I., Joas E., Dreyer A. et al. The evaluation of circulating endothelial progenitor cells and related angiogenic markers as prognostic factors in soft-tissue tumors. Eur J Surg Oncol 2018;44(4):496–501. DOI: 10.1016/j.ejso.2018.01.083.Frezzetti D., Gallo M., Roma C. et al. Vascular endothelial growth factor A regulates the secretion of different angiogenic factors in lung cancer cells. J Cell Physiol 2016;231(7):1514–21. DOI: 10.1002/jcp.25243.Yanagawa T., Shinozaki T., Watanabe H. et al. Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas. Exp Cell Res 2012;318(7):800–8. DOI: 10.1016/j.yexcr.2012.01.024.Wu H., Zhang Q., Zhao Y. et al. Association of sirtuin-1 and vascular endothelial growth factor expression with tumor progression and poor prognosis in liposarcoma. J Int Med Res 2020;48(6):1–10. DOI: 10.1177/0300060520926355.Kilvaer T.K., Smeland E., Valkov A. et al. The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk. BMC Clin Pathol 2014;14(1):5. DOI: 10.1186/1472-6890-14-5.Subbiah V., Meyer C., Zinner R. et al. Phase Ib/II study of the safety and efficacy of combination therapy with multikinase VEGF inhibitor pazopanib and MEK inhibitor trametinib in advanced soft tissue sarcoma. Clin Cancer Res 2017;23:4027–34. DOI: 10.1158/1078-0432.CCR-17-0272.Zhou X., Chen J., Xiao Q. et al. MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. Biosci Rep 2018;38(1):BSR20171017. DOI: 10.1042/BSR20171017. PMID: 29263143.Masoud G.N., Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 2015;5(5):378–89. DOI: 10.1016/j.apsb.2015.05.007.Ferrara N., Adamis A.P. Ten years of antivascular endothelial growth factor therapy. Nat Rev Drug Discov 2016;15(6):385–403. DOI: 10.1038/nrd.2015.17.Apte R.S., Chen D.S., Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell 2019;176(6):1248–64. DOI: 10.1016/j.cell.2019.01.021.Kampmann E., Altendorf-Hofmann A., Gibis S. et al. VEGFR2 predicts reduced survival in patients with soft tissue sarcomas. Patol Res Practice 2015;211:726–30. DOI: 10.1016/j.prp.2015.04.015.Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013;153(1):13–9. DOI: 10.1093/jb/mvs136.Ceci C., Atzori M.G., Lacal P.M., Graziani G. Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models. Int J Mol Sci 2020;21(4):1388–53. DOI: 10.3390/ijms21041388.Herbert S.P., Stainier D.Y. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011;12(9):551–64. DOI: 10.1038/nrm3176.Peach C.J., Mignone V.W., Arruda M.A. et al. Molecular pharmacology of vegf-a isoforms: binding and signalling at VEGFR2. Int J Mol Sci 2018;19(4):1264. DOI: 10.3390/ijms19041264.Vandekeere S., Dewerchin M., Carmeliet P. Angiogenesis revisited: an overlooked role of endothelial cell metabolism in vessel sprouting. Microcirculation 2015;22(7): 509–17. DOI: 10.1111/micc.12229.Simon T., Gagliano T., Giamas G. Direct effects of anti-angiogenic therapies on tumor cells: VEGF signaling. Trends Mol Med 2017;23(3):282–92. DOI: 10.1016/j.molmed.2017.01.002.Steinestel K., Wardelmann E. Metastasierung und progressionsmechanismen von weichteil-tumoren [Metastasis and progression mechanisms of soft tissue tumors. (In German)]. Pathologe 2015;36(Suppl. 2):167–70. DOI: 10.1007/s00292-015-0072-5. NNoebauer-Huhmann I.M., Grieser T. Weichteilsarkome: Wie lassen sich posttherapeutische Veränderungen von Rezidiven unterscheiden? [Soft tissue sarcoma: how can posttreatment alterations be distinguished from recurrences? (In German)]. Radiologe 2017;57(11):923–37. DOI: 10.1007/s00117-017-0310-3.Sugiura H., Tsukushi S., Yoshida M., Nishida Y. What is the success of repeat surgical treatment of a local recurrence after initial wide resection of soft tissue sarcomas? Clin Orthop Relat Res 2018;476(9):1791–800. DOI: 10.1007/s11999.0000000000000158.Felderhof J.M., Creutzberg C.L., Putter H. et al. Long-term clinical outcome of patients with soft tissue sarcomas treated with limbsparing surgery and postoperative radiotherapy. Acta Oncol 2013;52(4):745–52. DOI: 10.3109/0284186X.2012.709947.Nakamura T., Abudu A., Murata H. et al. Oncological outcome of patients with deeply located soft tissue sarcoma of the pelvis: a follow up study at minimum 5 years after diagnosis. Eur J Surg Oncol 2013;39(9): 1030–5. DOI: 10.1016/j.ejso.2012.12.019.Gazendam A.M., Popovic S., Munir S. et al. Synovial sarcoma: a clinical review. Curr Oncol 2021;28(3):1909–20. DOI: 10.3390/curroncol28030177.Wilson D.A.J., Gazendam A., Visgauss J. et al. Designing a rational follow-up schedule for patients with extremity soft tissue sarcoma. Ann Surg Oncol 2020;27(6): 2033–41. DOI: 10.1245/s10434-020-08240-z.Sun H.I., Akgun E., Bicer A. et al. Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence. Neurosurgery 2010;66(4):744–50. DOI: 10.1227/01.NEU.0000367553.65099.14.Kottke T., Evgin L., Shim K.G. et al. Subversion of NK-cell and TNFα immune surveillance drives tumor recurrence. Cancer Immunol Res 2017;5(11):1029–45. DOI: 10.1158/2326-6066.Gronchi A., Strauss D.C., Miceli R. et al. Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative rps working group. Ann Surg 2016;263(5):1002–9. DOI: 10.1097/SLA.0000000000001447.Yuan J., Li X., Yu S. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma. Cancer Control 2021;28:1–20. DOI: 10.1177/10732748211038424.Fares J., Fares M.Y., Khachfe H.H. et al. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 2020;5(1):28. DOI: 10.1038/s41392-020-0134-x.Bui N.Q., Wang D.S., Hiniker S.M. Contemporary management of metastatic soft tissue sarcoma. Curr Probl Cancer 2019;43(4):289–99. DOI: 10.1016/j.currproblcancer.2019.06.005.Blay J.Y. Sarcoma management: expertise and balance. Future Oncol 2021;17(21s):1. DOI: 10.2217/fon-2021-0448.Damerell V., Pepper M.S., Prince S. Molecular mechanisms underpinning sarcomas and implications for current and future therapy. Signal Transduct Target Ther 2021;6(1):6–246. DOI: 10.1038/s41392-021-00647-8.Cren P.Y., Lebellec L., Ryckewaert T., Penel N. Anti-angiogenic agents in management of sarcoma patients: overview of published trials. Front Oncol 2020;10:594445. DOI: 10.3389/fonc.2020.594445.Teng Р., Cai J. Using proteomimetics to switch angiogenic signaling January 2022. Acta Pharmaceutica Sinica 2022;12(3):1534–5. DOI: 10.1016/j.apsb.2022.01.016.Abdulkadir S., Li C., Jiang W. et al. Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor. J Am Chem Soc 2022;144(1):270–81. DOI: 10.1021/jacs.1c09571.Assareh E., Mehrnejad F., Mansouri K. et al. A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth. Biochem J 2019;476(4): 645–63. DOI: 10.1042/BCJ20180823.Ho V.C., Fong G.H. Vasculogenesis and angiogenesis in VEGF receptor-1 deficient mice. Methods Mol Biol 2015;1332:161–76. DOI: 10.1007/978-1-4939-2917-7_12.